CV of Symposium Speakers
Curriculum Vitae, Alberto Bedogni. University of Padova, Italy
Dr. Alberto Bedogni is Director of the Regional Center for Prevention, Diagnosis and Treatment of Medication and Radiation-related Bone Diseases of the Head and Neck since 2014. He is Assistant professor of Maxillofacial Surgery at the Department of Neurosciences-DNS, University of Padua, and Consultant at the Unit of Maxillofacial Surgery, Hospital Trust of Padua. His basic and clinical research focuses upon osteonecrosis of the jaws, bio-molecular markers in head & neck cancer, peripheral nerve regeneration, regenerative medicine and development of CAD-CAM customized titanium prototypes for jawbone reconstruction. He is coordinator of the Expert Panel Committee of the Italian Societies of Maxillofacial Surgery (SICMF) and Oral Medicine and Pathology (SIPMO) and is co-author of the Italian Recommendations for the prevention, diagnosis and treatment of MRONJ published in 2013. He also actively contributed to the preparation of the guidelines on prevention of bisphosphonate-related ONJ in the cancer population, on behalf of the Italian Ministry of Health (2014). He has been coordinator of a research team who published several clinical papers in the last 10 years on the prevention, treatment and pathogenesis of BRONJ and few of the very initial reports on bevacizumab and sunitinib-related ONJ. He contributed to develop an international network of clinical research centres and promoted several multicentre studies on MRONJ.
Curriculum Vitae, Stefano Fedele. University College London, Eastman Dental Institute, London, England
Stefano Fedele is Head of Department of Clinical Research and Full Professor of
Oral Medicine at University College London, Eastman Dental Institute. His
research activities focus upon clinical and translational research in Oral
Medicine with a special interest in MRONJ. Through international collaboration
he set up a network of centers collecting clinical data and DNA of a cohort of
MRONJ patients and drug-exposed controls to inform clinical and pharmacogenetic
(genetic predisposition) studies. He has led a team of international
investigators to publish a number of research papers on the non-exposed variant
of MORNJ, which led to the revision of MORNJ definition by the AAOMS.
Twenty-eight sites from seven countries have contributed to his Genome Wide
Association study (GWAs), which over the last 7 years has collected DNA from
~1,000 MRONJ patients and has identified, for the first time, a genetic variant
significantly associated with the risk of MORNJ development.
Curriculum Vitae, Roman Guggenberger. University of Zurich, Schwitzerland
Dr. Roman Guggenberger was born in Innsbruck, Austria where he studied medicine at the Medical University. After training and obtaining full license as a general practicioner in Austria, he moved to Zürich, Switzerland and finished his training in general radiology at the Department of Diagnostic and Interventional Radiology. He was fellow at the radiology department of the Orthopedic University Hospital in Zürich and subspecialized in musculoskeletal radiology and also performed a fellowship in pediatric neuroradiology at the Children`s Hospital in Zürich. He has obtained the Swiss diploma of diagnostic neuroradiology and became associate professor in 2016. Dr. Guggenberger is now a senior staff member and head of the musculoskeletal radiology imaging and research group at the Department of Diagnostic and Interventional Radiology in Zürich. He has spent most of this research career in evaluation and optimization of different imaging techniques for diseases of the musculoskeletal system. A strong focus of his work is on cone-beam CT in its various forms and peripheral nerve imaging. He has also published several works on bisphosphonate-induced osteonecrosis of the jaw and its detectability in different imaging techniques.
Curriculum Vitae, Ourania Nicolatou-Galitis. University of Athens, Greece
Ourania Nicolatou-Galitis, DDS, MSc, DrDEnt, Ourania Nicolatou-Galitis, www.nicolatou-galitis.com, www.dentaloncology.gr, www.dentaloncology.eu.
Oral Medicine, Oral Oncologist, Professor of the National and Kapodistrian University of Athens, Dental Oncology Unit, Dental School, dent.uoa.gr. Dr Ourania Nicolatou-Galitis graduated from the Dental School of the National and Kapodistrian University of Athens. She obtained her Master's Degree and Certificate in Oral Pathology from Temple University, Philadelphia, USA.
- Professor and Head, Clinic of Hospital Dentistry, 2010-present
- Responsible of the Graduate Program in Hospital Dentistry, 2010-present
- Founding member and President of the Hellenic Society of Oral Oncology, oraloncology.gr, 2005-present
- Founding member and member of the Board of the Hellenic Society of Head and Neck Cancer, headneckcancer.gr, 2016-present
- Past President of the International Society of Oral Oncology-ISOO, 2017-2019
- MASCC Strategic Planning Committee, mascc.org, 2017-2020
- Chair of the Bone Study Group, mascc.org, 2015-2020
Osteonecrosis of the jaw in medication is currently the main clinical and research focus of Dr Ourania Nicolatou-Galitis. She serves as a referral center for many Cancer Centers of Greece. She is the principal investigator for the AMGEN Registry Study for osteonecrosis in the Athens Dental School Center. As Chair of the Bone Study Group of MASCC, she has initiated a systematic review on the specific clinical questions (1) «to do or not to do the dental extraction» when a cancer patient receives medications related to osteonecrosis and (2) how to treat, when osteonecrosis develops.
Curriculum Vitae, Sven Otto. Ludwig-Maximilians-University of Munich, Germany
PD Dr. med. Dr. med. dent. Sven Otto has dealt intensively with clinical presentation, pathogenesis, prevention and treatment of medication-related osteonecrosis of the jaw. He has developed a pathogenesis theory putting infection and infection associated ph changes in the centre of the focus and collected cell cultural and clinical evidence for this hypothesis. He has also contributed to the clinical implementation of fluorescence-guided surgery for the treatment of MRONJ. Together with the AO research institute in Davos a minipig large animal model for MRONJ was established which could contribute to the further understanding of MRONJ. Together with Springer publishing he has edited the textbook "Medication-related osteonecrosis of the jaw: Bisphosphonates, Denosumab and New Agents".
- 1997-2006 Dental and medical studies at the university of Leipzig (Germany)
- 2006-2012: Specialty training for Oral and Maxillofacial Surgery, LMU München
- seit 05/2012: Board examination for Oral and Maxillofacial Surgery, LMU of Munich
- 2013: Habilitation dealing with „Bisphosphonate-related osteonecrosis of the jaw"
- since 2013 Senior Consultant of the department of Oral and Maxillofacial Surgery of Ludwig-Maximilians-University of Munich (Head: Professor Dr. Dr. Michael Ehrenfeld)
- 2014 Editor: Medication-Related Osteonecrosis of the Jaw: Bisphosphonates, Denosumab and New Agents" (published by Springer)
- 2015 Scientific Award of the German Association of Oral and Maxillofacial Surgery: „From cell culture over the large animal towards optimization of the prophylaxis and treatment of medication-related osteonecrosis of the jaw"
Bente Brokstad Herlofson
Curriculum Vitae, Bente Brokstad Herlofson. University of Oslo and Oslo University Hospital, Norway
Professor, specialist in oral and maxillofacial surgery at the Department of Oral Surgery and Oral Medicine, Faculty of Dentistry, University of Oslo and at the Department of Otorhinolaryngology – Head and Neck Surgery Division for Head, Neck and Reconstructive Surgery, Oslo University, University Hospital, Norway.
Participating scientist in the Scandinavian ONJ-cohort study, being the Principle investigator in Norway for the establishment of the Norwegian database for the enrolment of all ONJ cases related to antiresorptive treatment during 2011 until 2019. Contributed to the AO Foundation, AOCMF (Switzerland) booklet; Antiresorptive drug-related osteonecrosis of the jaw (ARONJ) – a guide to research, chapter 2; Clinical features of antiresorptive drug-induced osteonecrosis of the jaw, 2016.
Specific research interests: oral morbidity in cancer and cancer treatment, oral oncology, effects of anti-resorptive medication on bone and bone cells, osteonecrosis of the jaw, oral health related quality of life in cancer patient, oral late effects in patients treated for head- and neck cancer.
Sanne Werner Møller Andersen
Curriculum Vitae, Sanne Werner Møller Andersen. Rigshospitalet, Copenhagen University Hospital, Denmark.
Resident in Oral & Maxillofacial surgery at the Department of Oral & Maxillofacial Surgery, Rigshospitalet, Denmark.
Sanne has been part of the Copenhagen research team on MRONJ since 2014. She is now doing a feasibility study investigating rehabilitation of patients on high dose antiresorptive treatment or previous MRONJ with dental implants. Likewise she is investigating the possibility of apicoectomy due to apical periodontitis.
Sanne has participated in the multicenter genome study by Stefano Fedele, collecting DNA samples from MRONJ patients in Copenhagen.
Curriculum Vitae, Camilla Ottesen. Rigshospitalet, Copenhagen University Hospital, Denmark.
Dr. Camilla Ottesen is a PhD student at the Department of Oral Rehabilitation, Faculty of Health & Science at Copenhagen University and at the Department of Oral & Maxillofacial Surgery, Rigshospitalet (Copenhagen University Hospital) supervised by Professor Klaus Gotfredsen and Dr. Morten Schiødt. Camilla has been part of the Copenhagen research team on MRONJ since 2014. She has written a protocol for a randomized controlled trial investigating the importance of drug holiday in cancer patients on high dose antiresorptive medication, in relation to tooth extraction. Camilla is the main investigator of this drug holiday study. Furthermore, she is collaborator in another study of rehabilitation with dental implants in patients on high dose antiresorptive medication or with previous MRONJ.
Curriculum Vitae, Thomas Kofod. Rigshospitalet, Copenhagen University Hospital, Denmark
Dr Thomas Kofod is Head of Department of Oral and Maxillofacial Surgery at Rigshospitalet (Copenhagen University Hospital). His clinical and research activities focus upon corrective and reconstructive craniofacial and maxillofacial surgery including computer assisted surgery. In BRONJ especially computer assisted resection and reconstruction has been the focus of interest. In close collaboration with Morten Schiødt he parts the Copenhagen research team on BRONJ.
Curriculum Vitae, Morten Schiodt. Rigshospitalet, Copenhagen University Hospital, Denmark
Morten Schiodt is Senior Consultant, DDS, Dr. odont. Specialist Degree in Oral & Maxillofacial Surgery, Copenhagen (Rigshospitalet), Denmark, in 1979. Doctoral thesis on Oral Manifestations of Lupus Erythematosis in 1984. Teaching and organized symposia in 25 countries. Research on Sjogren's Syndrome, HIV/AIDS, and on Osteonecrosis of the jaws from antiresorptive treatment.
Chairman of the Department of Oral & Maxillofacial Surgery, Cph. Univ. Hospital 2001-2011. President of the Danish Association Oral & Maxillofacial Surgery for 6 years (1984-86 and 89-91), President of the Danish Society of Oral & Maxillofacial Surgery for 6 years (1996-2002), Assoc. Prof. University of California, San Francisco, USA, 1986-1989. Scientific reviewer 13 international Journals. Director of SICCA-Denmark founded in 2003, part of NIH-funded multicenter project leading to new classification of Sjogren's Syndrome. NIH funding 12.5 mill $. Author or co-author of 186 publications.
- Senior Maxillofacial Consultant at Department of Oral & Maxillofacial Surgery, Copenhagen University Hospital (Rigshospitalet) , Denmark
- 2003 – now: Director of SICCA Denmark. Part of multinational Sjogren project.
- 2010 - now: Director of Osteonecrosis Research at Copenhagen University Hospital, Denmark.
- 2010 - now: Director of Copenhagen ONJ Cohort (288 patients)
- 2011 – now: Scandinavian Coordinator for Scandinavian ONJ Database (Amgen XGEVA-363-study). 1000 patients enrolled.
- 2014 – now: European Lead Investigator for a Global Multicenter Case registry ONJ study (Amgen 2010-1102 study), 64 sites, 275 patients enrolled.
Download publication list